Nanobiotix: CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3

Related Keywords

Paris ,France General ,France ,Canada ,Texas ,United States ,French ,Brandon Owens ,Kate Mcneil ,Porter Novelli ,Kepler Cheuvreux ,Pierre Louis Germain ,Bart Van Rhijn ,Regulations Of The French Financial Markets Authority ,Exchange Commission On ,Linkedin ,French Financial Markets Authority Autorit ,Twitter ,Nanobiotix Communications ,Drug Administration ,Euronext ,Quarter Operational ,First Quarter Operational ,Registration Pathway ,Head Neck Cancer ,Local Control ,Single Agent Activated ,Advanced Cancers ,Priming Immune Response ,Head Neck Squamous Cell Carcinoma ,World Class Partners ,Validate Tumor Agnostic ,Combination Agnostic Therapeutic Profile ,Cancer Center ,Laurent Levy ,Registration Programs ,Reducing Operating ,Equity Line Financing ,Strengthen Financial ,General Regulations ,French Financial Markets Authority ,General Meeting ,Year Corporate ,Financial Update ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Investor Relations ,Louis Germain ,Nanobiotix ,Kcorrecting ,Eplacing ,Rovides ,First ,Quarter ,Perational ,Financial ,Update ,